Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer

被引：70
作者：
Haunschild, Carolyn E. [1 ,2 ]
Tewari, Krishnansu S. [2 ,3 ]
机构：
[1] Univ Calif Irvine, Dept Obstet & Gynecol, 333 City Blvd West,Suite 1400, Orange, CA 92868 USA
[2] Univ Calif Irvine, Div Gynecol Oncol, 333 City Blvd West,Suite 1400, Orange, CA 92868 USA
[3] Univ Calif Irvine, Dept Obstet Gynecol, City Tower,333 City Blvd,West Suite 1400, Orange, CA 92868 USA
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 07期
关键词：
bevacizumab; biological therapy; clinical trials; gynecologic; ovarian; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; ADVANCED EPITHELIAL OVARIAN; INTERVAL DEBULKING SURGERY; PRIMARY PERITONEAL; OPEN-LABEL; FALLOPIAN-TUBE; INTRAPERITONEAL CISPLATIN; NEOADJUVANT CHEMOTHERAPY;
D O I：
10.2217/fon-2019-0042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.
引用
收藏
页码：225 / 246
页数：22
相关论文
共 100 条
  • [1] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
    Aghajanian, Carol
    Goff, Barbara
    Nycum, Lawrence R.
    Wang, Yan V.
    Husain, Amreen
    Blank, Stephanie V.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 10 - 16
  • [2] Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer
    Aghajanian, Carol
    Goff, Barbara
    Nycum, Lawrence R.
    Wang, Yan
    Husain, Amreen
    Blank, Stephanie
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 105 - 110
  • [3] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [5] Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy
    Azad, Nilofer S.
    Annunziata, Christina M.
    Steinberg, Seth M.
    Minasian, Lori
    Premkumar, Ahalya
    Chow, Catherine
    Kotz, Herbert L.
    Kohn, Elise C.
    [J]. CANCER, 2008, 112 (08) : 1726 - 1732
  • [6] The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
    Backen, Alison
    Renehan, Andrew G.
    Clamp, Andrew R.
    Berzuini, Carlo
    Zhou, Cong
    Oza, Amit
    Bannoo, Selina
    Scherer, Stefan J.
    Banks, Rosamonde E.
    Dive, Caroline
    Jayson, Gordon C.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4549 - 4558
  • [7] Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?
    Backes, Floor J.
    Richardson, Debra L.
    McCann, Georgia A.
    Smith, Blair
    Salani, Ritu
    Eisenhauer, Eric L.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    O'Malley, David M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 833 - 838
  • [8] Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
    Bais, Carlos
    Mueller, Barbara
    Brady, Mark F.
    Mannel, Robert S.
    Burger, Robert A.
    Wei, Wei
    Marien, Koen M.
    Kockx, Mark M.
    Husain, Amreen
    Birrer, Michael J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11):
  • [9] Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
    Bamias, A.
    Gibbs, E.
    Lee, C. Khoon
    Davies, L.
    Dimopoulos, M.
    Zagouri, F.
    Veillard, A. -S.
    Kosse, J.
    Santaballa, A.
    Mirza, M. R.
    Tabaro, G.
    Vergote, I.
    Bloemendal, H.
    Lykka, M.
    Floquet, A.
    Gebski, V.
    Pujade-Lauraine, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1842 - 1848
  • [10] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
    Bennouna, Jaafar
    Sastre, Javier
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Maria Vieitez, Jose
    Bouche, Olivier
    Borg, Christophe
    Steffens, Claus-Christoph
    Alonso-Orduna, Vicente
    Schlichting, Christoph
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Andre, Thierry
    Kubicka, Stefan
    [J]. LANCET ONCOLOGY, 2013, 14 (01) : 29 - 37
12345678910